Terms: = Leukemia AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Treatment
1328 results:
1. Application and prognostic relevance of CD34 detection in immunophenotyping of pediatric acute B lymphoblastic leukemia.
Zha W; Yuan Y; Yang T; Zhu LJ; Kong WY; Zhuo JJ
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3384-3390. PubMed ID: 38766795
[TBL] [Abstract] [Full Text] [Related]
2. Improved Survival of Patients With Chronic Lymphocytic leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors.
Tadmor T; Melamed G; Alapi H; Gazit S; Patalon T; Rokach L
Anticancer Res; 2024 May; 44(5):2109-2115. PubMed ID: 38677726
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical Characteristics of CD4
He HS; Wei YF; Ji XY; Xu YH; Yang YQ; Jin XK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):588-594. PubMed ID: 38660871
[TBL] [Abstract] [Full Text] [Related]
4. Mycosis fungoides with large cell transformation (CD30+) and B-cell chronic lymphocytic leukemia.
Petković M; Ilić I; Jurakić Tončić R; Radman-Livaja I; Čeović R
Acta Dermatovenerol Croat; 2023 Dec; 31(4):223-224. PubMed ID: 38651850
[TBL] [Abstract] [Full Text] [Related]
5. Advancements in cancer immunotherapies targeting cd20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
Dabkowska A; Domka K; Firczuk M
Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
[TBL] [Abstract] [Full Text] [Related]
6. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
[TBL] [Abstract] [Full Text] [Related]
7. A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.
Collier-Bain HD; Emery A; Causer AJ; Brown FF; Oliver R; Dutton D; Crowe J; Augustine D; Graby J; Leach S; Eddy R; Rothschild-Rodriguez D; Gray JC; Cragg MS; Cleary KL; Moore S; Murray J; Turner JE; Campbell JP
Brain Behav Immun; 2024 May; 118():468-479. PubMed ID: 38503395
[TBL] [Abstract] [Full Text] [Related]
8. Evidence of the Role of Inflammation and the Hormonal Environment in the Pathogenesis of Adrenal Myelolipomas in Congenital Adrenal Hyperplasia.
Kolli V; Frucci E; da Cunha IW; Iben JR; Kim SA; Mallappa A; Li T; Faucz FR; Kebebew E; Nilubol N; Quezado MM; Merke DP
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473790
[TBL] [Abstract] [Full Text] [Related]
9. Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.
Zekri L; Hagelstein I; Märklin M; Klimovich B; Christie M; Lindner C; Kämereit S; Prakash N; Müller S; Stotz S; Maurer A; Greve C; Schmied B; Atar D; Rammensee HG; Jung G; Salih HR
Sci Transl Med; 2024 Mar; 16(737):eadh1988. PubMed ID: 38446900
[TBL] [Abstract] [Full Text] [Related]
10. Relevance of cd20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
Bommannan K; Arumugam JR; Radhakrishnan V; Sundersingh S
Br J Haematol; 2024 Apr; 204(4):1367-1374. PubMed ID: 38444113
[TBL] [Abstract] [Full Text] [Related]
11. Update on the management of relapsed/refractory chronic lymphocytic leukemia.
Bennett R; Seymour JF
Blood Cancer J; 2024 Feb; 14(1):33. PubMed ID: 38378673
[TBL] [Abstract] [Full Text] [Related]
12. The influence of cytotoxic drugs on the immunophenotype of blast cells in paediatric B precursor acute lymphoblastic leukaemia.
Prelog T; Bucek S; Brozic A; Peterlin J; Kavcic M; Omerzel M; Markelc B; Jesenko T; Prevodnik VK
Radiol Oncol; 2024 Mar; 58(1):133-144. PubMed ID: 38378030
[TBL] [Abstract] [Full Text] [Related]
13. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
Brillembourg H; Martínez-Cibrián N; Bachiller M; Alserawan L; Ortiz-Maldonado V; Guedan S; Delgado J
Br J Haematol; 2024 May; 204(5):1649-1659. PubMed ID: 38362778
[TBL] [Abstract] [Full Text] [Related]
14. Frontline Therapy of CLL-Changing treatment Paradigms.
Coombs CC
Curr Hematol Malig Rep; 2024 Apr; 19(2):65-74. PubMed ID: 38337108
[TBL] [Abstract] [Full Text] [Related]
15. Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines.
Mikulska M; Oltolini C; Zappulo E; Bartoletti M; Frustaci AM; Visentin A; Vitale C; Mauro FR
Blood Rev; 2024 May; 65():101180. PubMed ID: 38331696
[TBL] [Abstract] [Full Text] [Related]
16. Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA.
Ailawadhi S; Ravelo A; Ng CD; Shah B; Lamarre N; Wang R; Eakle K; Biondo JM
J Comp Eff Res; 2024 Feb; 13(2):e230119. PubMed ID: 38294335
[No Abstract] [Full Text] [Related]
17. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
Campanella A; Capasso A; Heltai S; Taccetti C; Albi E; Herishanu Y; Haggenburg S; Chatzikonstantinou T; Doubek M; Kättström M; Giannopoulos K; Simkovic M; Moreno C; Massaia M; Bumbea H; Alshemmari S; Ranghetti P; Perotta E; Martini F; Sant'Antonio E; Colia M; Combi C; Levi S; Kater AP; Hazenberg M; Nijhof IS; Hofsink Q; Demosthenous C; Kotaskova J; Zaleska J; Vrbacky F; Raya AM; Bisogno D; Tripoli IE; Popov VM; Roman V; Stavroyianni N; Karypidou M; Scarano E; Locatelli M; Frenquelli M; Scarfò L; Stamatopoulos K; Ghia P
Am J Hematol; 2024 Apr; 99(4):745-750. PubMed ID: 38264829
[TBL] [Abstract] [Full Text] [Related]
18. Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective treatment for Chronic Lymphocytic leukemia.
Raucci F; Vernieri C; Di Tano M; Ligorio F; Blaževitš O; Lazzeri S; Shmahala A; Fragale G; Salvadori G; Varano G; Casola S; Buono R; Visco E; de Braud F; Longo VD
Cancer Res; 2024 Apr; 84(7):1133-1148. PubMed ID: 38241703
[TBL] [Abstract] [Full Text] [Related]
19. Chronic Lymphocytic leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
Stumpf J; Al-Sawaf O
Curr Oncol Rep; 2024 Feb; 26(2):136-146. PubMed ID: 38175465
[TBL] [Abstract] [Full Text] [Related]
20. Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
[TBL] [Abstract] [Full Text] [Related]
[Next]
